The Latest Analyst Ratings For Editas Medicine
The Latest Analyst Ratings For Editas Medicine
Editas Medicine 的最新分析师评级
Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
在过去的三个月中，有4位分析师对Editas Medicine（纳斯达克股票代码：EDIT）进行了评估，提供了从看涨到看跌的不同观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $14.0, a high estimate of $20.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 27.27% from the previous average price target of $11.00.
分析师已经为Editas Medicine设定了12个月的目标股价，显示平均目标股价为14.0美元，最高估计为20.00美元，低估值为9.00美元。当前的平均价格从之前的平均目标价11.00美元上涨了27.27％，这是一个积极的转变。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析师评级：深度探索
An in-depth analysis of...
对分析师近...
登录免费看全文
登录/注册